Cardiology

Episodes 33-48 of 248

Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
CME/CE Broadcast Replay
Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
0.50 credits
- Iacopo Olivotto, MD
- Ahmad Masri, MD, MS
- Pablo Garcia-Pavia, MD, PhD
- Fabian Knebel, MD, PhD
- Caroline Coats, MD
0.50 credits
The Cost of Progress: Examining Barriers to ATTR-CM Care
The Cost of Progress: Examining Barriers to ATTR-CM Care
On the Frontlines of ATTR-CM
The Cost of Progress: Examining Barriers to ATTR-CM Care
- Charles Turck, PharmD, BCPS, BCCCP
- Michelle Kittleson, MD, PhD
Understanding Lipid and Lipoprotein Metabolism in Cardiovascular Health
Understanding Lipid and Lipoprotein Metabolism in Cardiovascular Health
Heart Matters
Understanding Lipid and Lipoprotein Metabolism in Cardiovascular Health
Diagnostic Gaps in ATTR-CM: Insights from a Multispecialty Survey in France
Diagnostic Gaps in ATTR-CM: Insights from a Multispecialty Survey in France
Heart Matters
Diagnostic Gaps in ATTR-CM: Insights from a Multispecialty Survey in France
ATTR-CM Care: Impact of Vutrisiran on Survival and Cardiovascular Events
ATTR-CM Care: Impact of Vutrisiran on Survival and Cardiovascular Events
Heart Matters
ATTR-CM Care: Impact of Vutrisiran on Survival and Cardiovascular Events
- Ryan Quigley
Vutrisiran for ATTR-CM: Impacts on Functional Capacity and Quality of Life
Vutrisiran for ATTR-CM: Impacts on Functional Capacity and Quality of Life
On the Frontlines of ATTR-CM
Vutrisiran for ATTR-CM: Impacts on Functional Capacity and Quality of Life
- Ryan Quigley
- Farooq Hameed Sheikh, MD
Sex-Based Differences in Lipid Management: Implications for Cardiovascular Risk
Sex-Based Differences in Lipid Management: Implications for Cardiovascular Risk
Heart Matters
Sex-Based Differences in Lipid Management: Implications for Cardiovascular Risk
Gender Bias and Heart Health: Improving Cardiovascular Care for Women
Gender Bias and Heart Health: Improving Cardiovascular Care for Women
Heart Matters
Gender Bias and Heart Health: Improving Cardiovascular Care for Women
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
CME/CE Broadcast Replay
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
0.50 credits
- Prof. Ulrich Laufs
- Pam R. Taub, MD, FACC, FASPC
- Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
- Christie Ballantyne, MD
0.50 credits
New Insights in the Management of HCM: Exploring the Clinical Spectrum
New Insights in the Management of HCM: Exploring the Clinical Spectrum
CME/CE Broadcast Replay
New Insights in the Management of HCM: Exploring the Clinical Spectrum
0.50 credits
- Milind Y. Desai, MD, MBA
- Iacopo Olivotto, MD
- Elena Arbelo, MD, PhD
0.50 credits
Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
CME/CE
Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
0.25 credits
- John McMurray, MD
- Scott Solomon, MD
0.25 credits
Effect of Vericiguat on Heart Failure Hospitalization Events in Ambulatory Patients With HFrEF: VICTOR Trial Prespecified Analysis
Effect of Vericiguat on Heart Failure Hospitalization Events in Ambulatory Patients With HFrEF: VICTOR Trial Prespecified Analysis
Cardiology
Effect of Vericiguat on Heart Failure Hospitalization Events in Ambulatory Patients With HFrEF: VICTOR Trial Prespecified Analysis
- Javed Butler, MD, MPH, MBA
VICTOR Trial Results: Regional Variation in Outcomes and Response to Vericiguat in Patients With HFrEF
VICTOR Trial Results: Regional Variation in Outcomes and Response to Vericiguat in Patients With HFrEF
Cardiology
VICTOR Trial Results: Regional Variation in Outcomes and Response to Vericiguat in Patients With HFrEF
- Carolyn Lam, MD
VICTOR Prespecified Analysis Results: Vericiguat Effects on Mortality in Ambulatory Patients With HFrEF
VICTOR Prespecified Analysis Results: Vericiguat Effects on Mortality in Ambulatory Patients With HFrEF
Cardiology
VICTOR Prespecified Analysis Results: Vericiguat Effects on Mortality in Ambulatory Patients With HFrEF
- Stephen Greene
VICTOR Trial Results: Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients With HFrEF
VICTOR Trial Results: Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients With HFrEF
Cardiology
VICTOR Trial Results: Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients With HFrEF
- Justin Ezekowitz, MD, MBBCh, MSc
Managing Cholesterol and Triglyceride Levels: Targeted Nutritional Approaches
Managing Cholesterol and Triglyceride Levels: Targeted Nutritional Approaches
Heart Matters
Managing Cholesterol and Triglyceride Levels: Targeted Nutritional Approaches

3/8

Episodes 33-48 of 248

Title

Share on ReachMD

Welcome to Global Cardiology Academy

Welcome to Global
Cardiology Academy